Diabetes elevates matrix metalloproteinase-9 (MMP-9) in the retina and its capillary cells, and activated MMP-9 damages mitochondria, accelerating retinal capillary cell apoptosis, a phenomenon which precedes the development of retinopathy. Diabetes also favors epigenetic modifications regulating the expression of many genes. DNA methylation is maintained by methylating-hydroxymethylating enzymes, and retinal DNA methyltransferase (Dnmt) is activated in diabetes. Our aim is to investigate the role of DNA methylation in MMP-9 regulation. The effect of high glucose on 5-methylcytosine (5mC) and 5-hydroxymethyl cytosine (5hmC), and binding of Dnmt1 and hydroxymethylating enzyme (Tet2) on MMP-9 promoter were quantified in retinal endothelial cells. Specific role of Tet2 in MMP-9 activation was validated using Tet2-siRNA. The results were confirmed in the retina from streptozotocin-induced diabetic mouse. Although glucose increased Dnmt1 binding at MMP-9 promoter, it decreased 5mC levels. At the same promoter site, Tet2 binding and 5hmC levels were elevated. Tet2-siRNA ameliorated increase in 5hmC and MMP-9 transcription, and protected mitochondrial damage. Diabetic mice also presented similar dynamic DNA methylation changes in the retinal MMP-9 promoter. Thus, in diabetes transcription of retinal MMP-9 is maintained, in part, by an active DNA methylation-hydroxymethylation process, and regulation of this machinery should help maintain mitochondrial homeostasis and inhibit the development/progression of diabetic retinopathy. Diabetic retinopathy remains one of the major causes of blindness in working adults. Many diabetes-mediated retinal metabolic abnormalities are implicated in its development, but the pathogenesis of this progressing disease remains complex. Our previous work has documented that diabetes activates retinal gelatinase matrix metalloproteinases (MMPs), and activated MMPs damage the mitochondria. The damaged mitochondria allow cytochrome C to leak into the cytosol, initiating apoptosis of capillary cells, 1-6 a phenomenon that is followed by the histopathology associated with diabetic retinopathy. 7 Transcription of MMP-9 gene is regulated by upstream sequences, which contain motifs with binding sites for transcriptional factors including NF-κB and AP-1. 8 In diabetes, MMP-9 transcription is upregulated in the retina and its capillary cells, and the binding of transcriptional factors NF-κB and AP-1 is increased at its promoter. 9 In addition to transcription factors, gene expression is also regulated by epigenetic modifications, and diabetes induces many such epigenetic modifications including DNA methylation and histone methylation/acetylation. 3, 10, 11 Methylation of the fifth carbon of cytosine (5-methylcytosine, 5mC) in the promoter or other upstream regulatory regions of a gene is generally associated with impaired binding of the transcription factors and repressed gene expression. 12,13 Although DNA methylation is necessary for establishment and maturation of cell fates, 14 and hypermethylation of retinal neurons onsets their programmed cell death, 15 aberrant DNA methylation is associated with many chronic diseases including cancer, diabetes, age-related macular degeneration and diabetic retinopathy. 12, 13, [16] [17] [18] In diabetes, retinal mitochondrial DNA (mtDNA) and the gene encoding the enzyme responsible for mtDNA biogenesis, polymerase γ1, are hypermethylated compromising the electron transport chain machinery and mtDNA biogenesis. 19, 20 DNA methylation is catalyzed by DNA methyltransferases (Dnmts); Dnmt3a and 3b are de novo enzymes, and Dnmt1 is a maintenance enzyme important in regulating tissue-specific patterns of the methylated cytosine. 21, 22 In diabetes, Dnmt activity is increased and the expression of Dnmt1 is elevated in the retina and its capillary cells. 20 Methylation of DNA is dynamically regulated both through passive and active
Diabetic retinopathy remains one of the major causes of blindness in working adults. Many diabetes-mediated retinal metabolic abnormalities are implicated in its development, but the pathogenesis of this progressing disease remains complex. Our previous work has documented that diabetes activates retinal gelatinase matrix metalloproteinases (MMPs), and activated MMPs damage the mitochondria. The damaged mitochondria allow cytochrome C to leak into the cytosol, initiating apoptosis of capillary cells, [1] [2] [3] [4] [5] [6] a phenomenon that is followed by the histopathology associated with diabetic retinopathy. 7 Transcription of MMP-9 gene is regulated by upstream sequences, which contain motifs with binding sites for transcriptional factors including NF-κB and AP-1. 8 In diabetes, MMP-9 transcription is upregulated in the retina and its capillary cells, and the binding of transcriptional factors NF-κB and AP-1 is increased at its promoter. 9 In addition to transcription factors, gene expression is also regulated by epigenetic modifications, and diabetes induces many such epigenetic modifications including DNA methylation and histone methylation/acetylation. 3, 10, 11 Methylation of the fifth carbon of cytosine (5-methylcytosine, 5mC) in the promoter or other upstream regulatory regions of a gene is generally associated with impaired binding of the transcription factors and repressed gene expression. 12, 13 Although DNA methylation is necessary for establishment and maturation of cell fates, 14 and hypermethylation of retinal neurons onsets their programmed cell death, 15 aberrant DNA methylation is associated with many chronic diseases including cancer, diabetes, age-related macular degeneration and diabetic retinopathy. 12, 13, [16] [17] [18] In diabetes, retinal mitochondrial DNA (mtDNA) and the gene encoding the enzyme responsible for mtDNA biogenesis, polymerase γ1, are hypermethylated compromising the electron transport chain machinery and mtDNA biogenesis. 19, 20 DNA methylation is catalyzed by DNA methyltransferases (Dnmts); Dnmt3a and 3b are de novo enzymes, and Dnmt1 is a maintenance enzyme important in regulating tissue-specific patterns of the methylated cytosine. 21, 22 In diabetes, Dnmt activity is increased and the expression of Dnmt1 is elevated in the retina and its capillary cells. 20 Methylation of DNA is dynamically regulated both through passive and active mechanisms; while passive DNA demethylation is mostly found in mitotic cells, active demethylation, in which oxidation of 5mC forms 5-hydroxymethylcytosine (5hmC), is mediated by ten-eleven translocation enzymes (Tets). [23] [24] [25] Hyperglycemic milieu activates Tets in zebrafish inducing a genome-wide demethylation and aberrant gene expression. 26 However, how altered DNA methylation machinery contributes to the development of diabetic retinopathy is unclear.
Although the promoter region of MMP-9 has relatively few CpG sites, DNA methylation is shown to modulate its transcription. 27, 28 The aim of this study is to investigate the dynamic DNA methylation of MMP-9 promoter in the development of diabetic retinopathy. Using retinal endothelial cells, one of the target cells of retinal histopathology characteristic of diabetic retinopathy, we investigated the effect of 20 mM D-glucose on the methylation-hydroxymethylation status of MMP-9 promoter. The specific role of the DNA methylation-hydroxymethylation was determined by regulating these enzymes by their specific siRNA, and the in vitro results were confirmed in the retina from diabetic mice.
MATERIALS AND METHODS Retinal Endothelial Cells
Retinal endothelial cells, prepared from bovine eyes, from 4th to 7th passage were incubated in normal (5 mM) or high (20 mM) D-glucose for 4 days, and parallel osmotic controls included cells incubated in 20 mM mannitol or 20 mM L-glucose. 9, 20 To investigate the effect of inhibition of Tet in demethylation of MMP-9 promoter, a batch of cells were incubated with a cell-permeable inhibitor (2S)-octyl-α-hydroxyglutarate (2-HG, 500 μM; Cayman, Ann Arbor, MI, USA). 29 The cells received fresh media, including 2-HG, every 24 h. Inhibition of Dnmts/Tets was further confirmed by transfecting the cells with their specific siRNAs (Dnmt1-siRNA (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and Tet2-siRNA (Integrative DNA Technology, Coralville, IA, USA)) using Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific, Rockford, IL, USA), as routinely performed in our laboratory. 9, 20 Parallel incubations with non-targeting scrambled RNA were used as transfection controls. After transfection, the cells were rinsed and incubated in either 5 or 20 mM D-glucose media for 4 days. The efficiency of transfection was determined by quantifying their protein (western blot) and gene (SYBR Green-based quantitative real-time PCR (qPCR)) expressions.
Animal Models
Eight-week-old C57BL/6J mice were randomly assigned to normal and diabetes group. Diabetes was induced by streptozotocin (intraperitoneally; 55 mg/kg BW) for 4 consecutive days, and 2 days after the last injection, animals presenting blood glucose over 250 mg/dl were considered as diabetic. Animals in the diabetic group received daily insulin injection (0.1-0.3 IU, NPH) to prevent weight loss and dehydration. The mice were killed 6 months after induction of diabetes by using carbon dioxide, and retina were collected Chromatin Immunoprecipitation To analyze potential interactions between DNA and epigenetic machinery, chromatin immunoprecipitation (ChIP) assay was performed using the methods routinely performed in our laboratory. 9, 20 Briefly, paraformaldehyde crosslinked samples were sonicated six times for 10 s each using a Sonic Dismembrator (Model 100; Thermo Fisher Scientific) at a setting 6 for retina and 4 for endothelial cells. Quantification of 5mC and 5hmC Sonicated DNA was immunoprecipitated for 5mC/5hmC using methylated/hydroxymethylated DNA Immunoprecipitation (MeDIP/hMeDIP) Kits (EPIGENTEK, Farmingdale, NY, USA). The enriched 5mC/5hmC fractions were analyzed by qPCR using species-specific MMP-9 primers (Table 1) , as recently reported by us. 20 The products were confirmed by semiquantitative PCR on a 2% agarose gel.
Western Blot
Protein (30-40 μg) was separated on a 4-20% gradient acrylamide gel (Bio-Rad, Hercules, CA, USA). The proteins transferred onto nitrocellulose membranes were detected using antibodies against the proteins of interest (Dnmt1 and Tet2 from Abcam, and β-actin cat. no. A-5316 from SigmaAldrich, St Louis, MO, USA). Images were quantified by the Carestream MI software (Carestream, Rochester, NY, USA), and the intensities of the target bands were normalized to those of the loading control, β-actin.
Gene Transcripts
Gene transcripts were quantified by qPCR using targetspecific primers. Amplification program included the holding stage at 50°C for 2 min and 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 15 s, annealing and extension at 60°C for 1 min, and 72°C for 5 min. Reaction specificity was validated by a single peak in the melting curve. For MMP-9, TaqMan qPCR was performed. Values of the products were normalized to the cycle threshold (Ct) value from the input sample, and those in cDNA were normalized to the Ct values from β-actin in the same sample. Relative fold changes were calculated by considering the values obtained from cells in 5 mM glucose or normal mice as one. 4, 9, 20 Enzyme Activities of Dnmt and Tet The global activities of Dnmt and Tet were determined in nuclear fractions using EpiQuik DNA Methyltransferase Activity/Inhibition and Epigenase 5mC-Hydroxylase TET Activity/Inhibition Assay Kits (EpiGentek), respectively. Briefly, nuclear extracts (3-6 μg for Dnmt or 10-20 μg for Tet activity) was added to the microplates coated with enzyme substrates, and the reaction products were detected by following the manufacturer's instructions.
Mitochondrial Damage
Mitochondrial damage was evaluated by quantifying the gene transcripts of mtDNA-encoded cytochrome b (Cytb) of complex III and ND6 of complex I, as reported previously. 4, 9, 20 Statistical Analysis Results were analyzed using SigmaPlot (Systat, Chicago, IL, USA), and the data are presented as mean ± standard deviations. Statistical test between two groups was carried out by t-test or Mann-Whitney rank-sum test. For multiple comparisons for the data with normal distribution, one-way ANOVA followed by Student-Newman-Keuls test was performed, and for the data that did not qualify the normal distribution pattern, one-way analysis on ranks followed by Dunn's test were used. A P-value o0.05 was considered as statistically significant. Due to the dynamic nature of DNA methylation, methylated cytosine can be converted to 5hmC; 23, 24 to understand the mechanism for decreased 5mC levels at the MMP-9 promoter, in spite of increased Dnmt1 binding, 5hmC levels were quantified. 5hmC levels at the MMP-9 promoter were increased by three fold in the cells incubated in high D-glucose compared with the cells in 5 mM D-glucose or 20 mM mannitol (Figure 3a) . The role of demethylation in MMP-9 transcription was confirmed by supplementing 20 mM D-glucose medium with an inhibitor of the hydroxymethylation enzymes; addition of 2-HG, in addition to preventing glucose-induced increase in Tet activity (Figure 3b) , also ameliorated increase in MMP-9 transcripts (Figure 3c ).
RESULTS

Retinal Endothelial Cells
Tet family of enzymes has three major members, Tet1, Tet2, and Tet3; 24, 30 to determine the specific isoform(s) responsible for hypomethylation of MMP-9 promoter, the effect of 20 mM D-glucose on their expressions was quantified. Although 20 mM D-glucose had no effect on Tet1 and Tet3, Tet2 expression (protein and gene) was significantly increased compared with the values obtained from cells in normal glucose (Figure 4a ). The role of Tet2 in hydroxymethylation of 5mC was confirmed by its binding at the MMP-9 promoter using ChIP technique; consistent with increase in 5hmC levels, Tet2 binding was also elevated by over fourfold in cells incubated in 20 mM D-glucose. In the same samples, IgG controls were o1% compared with the values obtained using Tet2 antibody (Figure 4b ). Regulation of Tet2 by its specific siRNA prevented 20 mM D-glucoseinduced increase in 5hmC levels, and, surprisingly, ameliorated decrease in 5mC levels at the MMP-9 promoter. In the same cell preparation, transcriptional activation of MMP-9 was also protected (Figure 5a) . Activated MMP-9 damages retinal mitochondria initiating capillary cell apoptosis, which precedes the development of degenerative capillaries in the retinal microvasculature. 4 The protective effect of inhibition of hydroxymethylation was confirmed by quantifying transcription of mtDNA. 
Diabetic Animal Model
Consistent with the results from isolated retinal endothelial cells in high D-glucose, diabetes decreased 5mC levels in the promoter region (−640 to − 356) of the retinal MMP-9, compared with the values from nondiabetic normal mice. However, 5mC levels in the intragenic CpG island region (1361-1600) remained unchanged in the retina from normal and diabetic mice ( Figure 6a ). As expected, 4, 9 in the same diabetic animals, retinal MMP-9 transcripts were significantly higher compared with those from normal mice (Figure 6b) .
Dnmt is activated in the retina in diabetes, 20 and consistent with the results from diabetic rats and retinal endothelial cells in high D-glucose, among the members of the Dnmt family, the expression of Dnmt1 was significantly elevated (Figure 6c) . To investigate the role of Dnmt1 in the regulation of retinal MMP-9 promoter methylation status, its binding at the MMP-9 promoter was determined. Figure 6d shows a significant increase in Dnmt1 binding at the MMP-9 promoter; the values obtained from diabetic mice were over twofold higher compared with the nondiabetic mice. Similar discrepancies between increase in Dnmt1 binding but decrease in 5mC levels at the MMP-9 promoter by high glucose in retinal endothelial cells and in the retina from diabetic mice support an active demethylation of the MMP-9 promoter.
To further confirm the role of active hypomethylation in transcriptional activation of MMP-9 in diabetes, 5hmC levels were quantified; as shown in Figure 7a , 5hmC levels at the MMP-9 promoter were increased by over 2.5-fold in the retina from diabetic mice compared with that from age-matched normal mice. In the same retina samples, global Tet activity was also elevated by~75% (Figure 7b) , and among the three members of Tet family, only Tet2 expression (mRNA and protein) showed significant increase in the retina from diabetic mice compared with the retina from nondiabetic mice (Figure 7c ). Diabetes also elevated Tet2 binding at the MMP-9 promoter by over threefold (Figure 7d) , further confirming the role of Tet-mediated hypomethylation in MMP-9 transcriptional activation in diabetes.
DISCUSSION
Diabetes alters expressions of genes implicated in the metabolic abnormalities including genes encoding proteins for mitochondrial biogenesis and proinflammatory cytokines. 3,31,32 MMP-9 expression and mitochondrial accumulation are elevated in the retina and its capillary cells in diabetes, and increased MMP-9 damages mitochondrial membrane, activating the apoptotic machinery, a phenomenon that precedes the development of diabetic retinopathy. 4, 7, 9, 33, 34 Although gene expression is mainly Figure 6 Diabetes hypomethylates matrix metalloproteinase-9 (MMP-9) promoter, but the binding of DNA methyltransferase (Dnmt1) in the same region is increased. (a) The levels of 5-methylcytosine (5mC) were quantified in the promoter (−640 to − 356) and the intragenic CpG island (1361-1600) regions of the MMP-9 gene by methylated DNA Immunoprecipitation Kit. Total genomic DNA obtained from normal mouse retina served as input DNA control. Gene transcripts of (b) MMP-9, and (c) Dnmts were quantified by SYBR green-based quantitative realtime PCR (qPCR) using β-actin as the housekeeping gene. (d) The binding of Dnmt1 at the MMP-9 promoter region was measured in the crosslinked retina by immunoprecipitating the samples with Dnmt1 antibody, followed by amplification of the promoter region by qPCR. Immunogobulin G (IgG) was used as a negative antibody control (indicated as^), and Ct values were normalized with the values from input by ddCt method. Values are represented as mean ± s.d. from five to seven mice in each group. Norm and Diab = retina from nondiabetic normal mouse or from diabetic mouse respectively. *Po0.05 compared with normal. Figure 7 The levels of 5-hydroxymethylcytosine (5hmC) are increased at the retinal matrix metalloproteinase-9 (MMP-9) promoter in diabetes, and hydroxymethylation enzyme machinery is activated. (a) 5hmC levels were quantified at the promoter region in sonicated DNA using hMeDIP Immunoprecipitation Kit. The total genomic DNA obtained from normal mouse retina was used as an input DNA control. modulated by the transcriptional factors, it can also be regulated by metabolite fluctuations, and these epigenetic modifications alter gene expression without altering the DNA sequence. 11, 35 We have shown that in the pathogenesis of diabetic retinopathy, histones in the retinal MMP-9 promoter are epigenetically modified, increasing the binding of NF-κB and AP-1. 6, 9, 34 Here, our exciting data obtained from both in vitro (retinal capillary cells that are the target of histopathology characteristic of diabetic retinopathy) and in vivo (retina from diabetic rodents) models show that the hyperglycemic milieu also alters the methylation status of MMP-9 promoter. Despite decreased 5mC in the promoter region, the binding of the Dnmt1 is increased, but a concomitant activation of the demethylation machinery keeps the MMP-9 promoter hypomethylated, resulting in its increased transcription. Silencing of the cytosine hydroxymethylation enzyme Tet2 prevents hyperglycemia-induced increase in 5hmC and MMP-9 transcription, and maintains mitochondrial homeostasis. These results clearly suggest that in diabetes active cytosine methylation-demethylation process of the MMP-9 promoter has a significant role in its transcriptional activation, and regulation of the cytosine methylation-demethylation machinery could inhibit the development/progression of diabetic retinopathy by preventing MMP-9-mediated mitochondrial damage.
Aberrant DNA methylation is considered as an important mechanism of gene regulation. In normal cells, DNA methylation is associated with organization of chromatin into active and inactive state, regulation of gene expression, and tissue-specific expression and genomic imprinting. 36, 37 DNA methylation often represses gene transcription by interfering with the binding of the transcription factor, and/or recruitment of other factors to form repression complex. 38 The process acts as an interplay between external factors and genome, and is affected by many external factors including drugs and disease severity. 10,24 MMP-9 promoter has relatively few CpG islands, but it contains many CpG sites; 27, 28 the results presented here show that diabetes decreases 5mC levels in the promoter region of retinal MMP-9. Although methylation of the intragenic CpG islands can also regulate the gene expression, 39 we show that hyperglycemia has no effect on the intragenic region of the MMP-9 gene, suggesting that DNA methylation of the promoter is critical in regulating its transcription. The promoter regions used in our study includes the binding sites of the transcription factors essential for MMP-9 transcription, such as NF-κB and Sp1, and reduced 5mC levels in this region indicate that hypomethylation of this region could be favoring the recruitment of these transcriptional factors. Consistent with this, hypomethylation of MMP-9 promoter in other tissues is shown to influence the binding of NF-κB, and regulate its active transcription, 27, 28 and in diabetes, the binding of NF-κB and AP-1 is increased at the retinal MMP-9 promoter. 34 The possibility that hypomethylation of MMP-9 promoter could be repressing the binding of the repressor proteins methyl-CpG-binding protein-2, which can interfere with the transcription machinery by binding to methyl-CpG pair, 40 however, cannot be ruled out.
Despite hypomethylation of MMP-9 promoter, to our surprise, the binding of Dnmt1 is significantly elevated at the same region, and regulation of Dnmt1 by its siRNA further decreases 5mC levels at the MMP-9 promoter. These results clearly support concomitant activation of a demethylation process. Activation of demethylation is further supported by our data showing increased activity of the hydroxymethylating enzyme in the retina, elevated 5hmC levels in the same region of the MMP-9 promoter, and amelioration of glucoseinduced increase in MMP-9 transcription by Tet inhibitor. Thus, although activation of Dnmt increases its binding, concurrent activation of the hydroxymethylation machinery keeps MMP-9 promoter hypomethylated, facilitating the transcription process. In support, others have shown an inverse correlation between DNA methylation and MMP-9 transcription in mouse thymic lymphoma cell line. 27 Although Tet family has three major members, 24, 30 we show that in diabetes Tet2 is the most affected member in the retina and its capillary cells. The role of Tet2 in regulating active demethylation of the MMP-9 promoter is further confirmed by its increased binding at the same promoter region, and also by its siRNA, which, in addition to preventing glucoseinduced increase in 5hmC, also prevents decrease in 5mC and protects increase in MMP-9. Amelioration of diabetesinduced increase in mtDNA damage and decrease in its transcription further confirms the role of Tet in diabetic retinopathy. We recognize that although demethylation could be initiated and processed by multiple pathways including passive dilution and deamination, 23, 24 capillary cells do not actively proliferate after birth, abating the possibility of a replication-dependent passive dilution assisting in the loss of methylation of the MMP-9 promoter seen here in the retinal endothelial cells. Our in vivo experiments were performed in the retina, a complex tissue with multiple layers and cell type; however, similar results from retinal endothelial cells in culture and retina from diabetic rodents support retinal MMP-9 regulation in diabetes by a dynamic DNA methylation process.
The present study is focused on DNA methylationdemethylation of the MMP-9 promoter; however, hypomethylation of H3K9 is also observed in diabetes, and this frees up that lysine 9 of H3K9 for acetylation, facilitating the recruitment of NF-κB. 9 Consistent with multiple epigenetic modifications seen in the retinal MMP-9 promoter in diabetes, others have shown correlation among broad changes in H3K9 acetylation by high glucose, DNA hypomethylation and gene induction. 36 Furthermore, MMP-9 is also regulated by its intracellular tissue inhibitor, TIMP-1, whose levels are decreased in the retina in diabetes; 5 thus, its role in regulating retinal MMP-9 activity cannot be ruled out.
Recent studies have suggested that 5hmC is critical in various important normal processes, such as ion transport, transcription, cell adhesion, and cell death, 23, 41 and it is now considered not only as an intermediate in demethylation but also as an independent epigenetic marker whose altered levels are observed in many chronic diseases including cancer and Rett syndrome. 41, 42 Tet activation is being implicated in many diseases, including diabetic complications, Alzheimer's, and liver cancer. 24, 26, 38, 43, 44 Hyperglycemia in zebrafish activates Tet 26 and induces a genome-wide demethylation and aberrant gene expression. 45 Site-specific demethylation of MMP-9 promoter is shown to have an important role in the pathogenesis of diabetic refractory ulcers, 28 and here, we show that the regulation of hypomethylation of retinal MMP-9 promoter regulates its transcription and prevents mitochondrial damage. MMP-9 has important role in the pathogenesis of diabetic retinopathy, and mice with MMP-9 gene regulated are protected from the development of diabetic retinopathy, 4, 33, 34 thus suggesting that the regulation of methylation of MMP-9 could serve as an important target in maintaining mitochondrial homeostasis, and the development of diabetic retinopathy.
